RBC Capital Maintains a Hold Rating on Gilead Sciences (GILD)

Group 1 - Gilead Sciences, Inc. (NASDAQ:GILD) is recognized as one of the best medical stocks to buy currently, with a Hold rating maintained by RBC Capital analyst Brian Abrahams and a price target set at $98.00 [1] - For fiscal Q2 2025, Gilead reported a 2% growth in total revenues, reaching $7.1 billion, attributed to increased sales of HIV treatments, Livdelzi, and Trodelvy [2] - The diluted EPS for the quarter was $1.56, an increase from $1.29 in the prior year, driven by net unrealized gains on securities and higher product sales [3] Group 2 - Gilead's portfolio includes drugs targeting serious diseases such as cancer, HIV, viral hepatitis, and COVID-19, focusing on medical areas with unmet needs [4] - The company operates in over 35 countries, indicating a broad international presence [4]